Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours
Written by
PharmaTimes
Published
0
comments
0
min
Early data reveals strong response rates in ovarian cancer cohort Early data reveals strong response rates in ovarian cancer cohort